Work

Efficacy and safety of BEBT-209, a primary CDK4 inhibitor, in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer.

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e15144

Authors: Quchang Ouyang, Yongkui Lu, Huihui Li, Jiuwei Cui, Yunjiang Liu, Tao Wu, Tao Sun, Jun Xiao, Changgeng Qian, Qiang Liu

Institutions: Hunan Cancer Hospital, Guangxi Medical University, Shandong Tumor Hospital, First Hospital of Jilin University, Fourth Hospital of Hebei Medical University, Central South University, Liaoning Cancer Hospital & Institute, First People's Hospital of Xianyang, Sun Yat-sen University, Sun Yat-sen Memorial Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410817343

FWCI:

Cites:

Cited by:

Related to: 10